<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="and active prevention, worldwide. Although we are confident that a" exact="treatment" post="will eventually be found, no specific vaccines or ideal"/>
 <result pre="significance of promising drugs based on these targets in the" exact="treatment" post="of SARSâ€�CoVâ€�2. We hope this review will facilitate the"/>
 <result pre="Epidemiological surveys have found that the clinical features of SARSâ€�CoVâ€�2" exact="infection" post="are similar to those of SARSâ€�CoV and are characterized"/>
 <result pre="cases and mortality are rapidly increasing daily, with only symptomatic" exact="treatment" post="available. This situation means that research to confirm potential"/>
 <result pre="possible transmission, infection, and pathogenesis cycle of SARSâ€�CoVâ€�2. In the" exact="infection" post="phase, SARSâ€�CoVâ€�2 attaches to the cellular receptor via the"/>
 <result pre="and drug R&amp;amp;D institutions to provide passive immunization against the" exact="infection" post="(Ahmed, Quadeer, &amp;amp; McKay, 2020). According to the functional"/>
 <result pre="of 0.19 Î¼M, suggesting that EK1 is also a promising" exact="treatment" post="as a SARSâ€�CoVâ€�2 drug pending verification and development. According"/>
 <result pre="cell membrane ACE2 protein, thus preventing the entry and subsequent" exact="infection" post="by SARSâ€�CoVâ€�2. This promising intervention strategy was shown to"/>
 <result pre="experiments, but additional tests are needed to identify any antiâ€�SARSâ€�CoVâ€�2" exact="infection" post="effects (Li et al., 2003). Alternatively, people could simply"/>
 <result pre="quite promising and it would be feasible to inhibit SARSâ€�CoVâ€�2" exact="infection" post="of cells, including Veroâ€�E6 cells, human capillary organoids, and"/>
 <result pre="that ACE2 must be a potential therapeutic target in the" exact="treatment" post="of SARSâ€�CoVâ€�2. Meanwhile, an ACE2 antibody, ACE2â€�scFv, ACE2 nanobody,"/>
 <result pre="nanobody, and ACE2â€�Fc may be promising antiâ€�SARSâ€�CoVâ€�2 drugs after animal" exact="testing" post="and clinical trials. 3.3 Potential TMPRSS2 targets and promising"/>
 <result pre="TMPRSS2 should be considered a potential therapeutic target for the" exact="treatment" post="of SARSâ€�CoVâ€�2â€�infected patients. More remarkably, camostat mesylate has already"/>
 <result pre="camostat mesylate has already been approved for safety for the" exact="treatment" post="of pancreatic inflammatory disease in Japan, which reminds us"/>
 <result pre="nafamostat mesylate may also be a promising inhibitor of SARSâ€�CoVâ€�2" exact="infection" post="by targeting TMPRSS2 (Inoue, 2020). As these two drugs"/>
 <result pre="disease processes, such as tumour progression, plasmodium invasion, and virus" exact="infection" post="(Lu et al., 2018; Nguyen &amp;amp; Kamil, 2018; Zhang"/>
 <result pre="peptide (AP)â€�9 has high binding activity to effectively prevent SARSâ€�CoV" exact="infection" post="of HEK293 cells (Chen et al., 2005). Due to"/>
 <result pre="and SARSâ€�CoV, CD147 may be a potential target for the" exact="treatment" post="of SARSâ€�CoVâ€�2. To test this hypothesis, Wang et al."/>
 <result pre="localization and binding status of CD147 and S protein during" exact="infection" post="and observed that the S protein and CD147 were"/>
 <result pre="or an equally important new receptor. Additionally, whether the combined" exact="treatment" post="is better than alternative treatment needs to be confirmed"/>
 <result pre="receptor. Additionally, whether the combined treatment is better than alternative" exact="treatment" post="needs to be confirmed by additional in vivo and"/>
 <result pre="recognized as one of the most important means for the" exact="treatment" post="of SARSâ€�CoV. Although SARSâ€�CoV shares approximately 82% sequence identity"/>
 <result pre="Nakamura, 2017). A favipiravir clinical trial (ChiCTR2000029600) for treating SARSâ€�CoVâ€�2" exact="infection" post="achieved the expected results. In the clinical trial, a"/>
 <result pre="and relatively high patient compliance was noted in the favipiravir" exact="treatment" post="group, indicating that favipiravir is a potential antiâ€�SARSâ€�CoVâ€�2 drug"/>
 <result pre="Wang et al. found that remdesivir can effectively prevent the" exact="infection" post="of SARSâ€�CoVâ€�2 at a very low concentration with a"/>
 <result pre="is very likely to be a potential drug against SARSâ€�CoVâ€�2" exact="infection" post="(Wang, Cao et al., 2020). Furthermore, a report that"/>
 <result pre="al., 2020). Furthermore, a report that remdesivir achieved the expected" exact="treatment" post="effect in a patient infected with SARSâ€�CoVâ€�2 in the"/>
 <result pre="Phase III clinical trial stage, shedding new light on the" exact="treatment" post="of SARSâ€�CoVâ€�2â€�induced disease. Based on the above research, RdRP"/>
 <result pre="the important roles of PLpro in the virus replication and" exact="infection" post="processes. A recent study demonstrated that PLpro in SARSâ€�CoVâ€�2"/>
 <result pre="PLpro should be considered a potential enzyme target for the" exact="treatment" post="of SARSâ€�CoVâ€�2. As research continues, several Xâ€�ray crystallography studies"/>
 <result pre="the most crucial proteases for RdRP generation, virus replication, and" exact="infection" post="(Zhou et al., 2019). Similar to the RdRP protein,"/>
 <result pre="is expected to become another potential enzyme target for the" exact="treatment" post="of SARSâ€�CoVâ€�2. Lopinavir and ritonavir, two inhibitors of 3CLpro,"/>
 <result pre="ritonavir may also be promising drugs for SARSâ€�CoVâ€�2 treatment. Interestingly," exact="treatment" post="with a formulation of lopinavir and ritonavir in tablet"/>
 <result pre="agents with potential antiviral activity against SARSâ€�CoVâ€�2 after virtual drug" exact="screening" post="(in silico and enzyme activity test) on January 25,"/>
 <result pre="and ritonavir. Even though this combination has produced a high" exact="screening" post="score, its effectiveness remains controversial due to the accidental"/>
 <result pre="Zhu, Lu, et al., 2020). Although hopes are fading for" exact="treatment" post="with lopinavir and ritonavir, targeting 3CLpro is still a"/>
 <result pre="et al. found nine promising low MW inhibitors for the" exact="treatment" post="of SARSâ€�CoVâ€�2 after optimization based on targeting 3CLpro by"/>
 <result pre="may provide important insights and promising therapeutic targets for SARSâ€�CoVâ€�2" exact="treatment" post="(Ahn et al., 2009; Asha et al., 2018; Qureshi,"/>
 <result pre="may be a potential biological agent for consideration as a" exact="treatment" post="strategy to kill SARSâ€�CoVâ€�2. Two patents in Korea present"/>
 <result pre="another potential biological agent for combating SARSâ€�CoVâ€�2, similar to the" exact="treatment" post="of SARSâ€�CoV. ASOs have also been designed to detect"/>
 <result pre="may be a class of biological agents useful for the" exact="treatment" post="of SARSâ€�CoVâ€�2, similar to the situation for SARSâ€�CoV. In"/>
 <result pre="ILâ€�6 secretion, which further aggravate the inflammatory response after SARSâ€�CoVâ€�2" exact="infection" post="(Li et al., 2020; Zhou et al., 2020). Recently,"/>
 <result pre="et al., 2020; Verhoeven et al., 2019). To date, a" exact="treatment" post="programme utilizing tocilizumab based on conventional therapy has been"/>
 <result pre="oxygenation index of respiratory function. After 2 weeks of careful" exact="treatment" post="by the scheme, 19 patients recovered, and only one"/>
 <result pre="ill due to critical illness (Zhou et al., 2020). This" exact="treatment" post="programme utilizing tocilizumab based on conventional therapy has been"/>
 <result pre="targeting the inflammatory cytokine storm on the basis of conventional" exact="treatment" post="(Xinhua Daily, 2020). Ge et al. reported a polyâ€�ADPâ€�ribose"/>
 <result pre="apparent toxicity, which makes it a valuable candidate for the" exact="treatment" post="of inflammatory cytokine storms induced by SARSâ€�CoVâ€�2. Above all,"/>
 <result pre="SARSâ€�CoVâ€�2. Above all, the basic research and results of clinical" exact="treatment" post="with tocilizumab and CVL218 based on conventional therapy remind"/>
 <result pre="passive strategy has been shown to be effective in the" exact="treatment" post="of other viral diseases (Mire et al., 2016). Based"/>
 <result pre="(Mire et al., 2016). Based on experience, patients with resolved" exact="infection" post="will develop viral antibodies at a high titre in"/>
 <result pre="medical care, this proposal is the simplest and most feasible" exact="treatment" post="under consideration (Thorpe, Masser, Nguyen, &amp;amp; Davison, 2020). At"/>
 <result pre="Chinese medicine to treat infections caused by SARSâ€�CoVâ€�2 As SARSâ€�CoVâ€�2" exact="infection" post="has become more rampant worldwide, there is an equally"/>
 <result pre="(TCM), and now, significant progress has been achieved in the" exact="treatment" post="of SARSâ€�CoVâ€�2. Since January 25, 2020, the early intervention"/>
 <result pre="and development of promising TCM compounds and extracts for the" exact="treatment" post="of SARSâ€�CoVâ€�2. 4 CONCLUDING REMARKS Although the outbreak of"/>
 <result pre="efficacy and safety of these promising candidate drugs in the" exact="treatment" post="of SARSâ€�CoVâ€�2 need to be confirmed in further preclinical"/>
 <result pre="block the outbreak of SARSâ€�CoVâ€�2 worldwide, we hope that the" exact="infection" post="and transmission of this virus will recede in a"/>
 <result pre="S. W., â€¦ Oh, J. W. (2009). RNA aptamerâ€�based sensitive" exact="detection" post="of SARS coronavirus nucleocapsid protein. Analyst, 134(9), 1896â€&quot;1901. 10.1039/b906788d19684916"/>
 <result pre="S., Bebeacua, C., Blangy, S., â€¦ Cambillau, C. (2013). Viral" exact="infection" post="modulation and neutralization by camelid nanobodies. Proceedings of the"/>
 <result pre="Feng, G., â€¦ Chen, Q. (2020). The course of clinical" exact="diagnosis" post="and treatment of a case infected with coronavirus disease"/>
 <result pre="â€¦ Chen, Q. (2020). The course of clinical diagnosis and" exact="treatment" post="of a case infected with coronavirus disease 2019. Journal"/>
 <result pre="Passive immunotherapy: Assessment of convalescent serum against Ebola virus Makona" exact="infection" post="in nonhuman primates. The Journal of Infectious Diseases, 214(suppl"/>
 <result pre="â€¦ Morikawa, S. (2006). Inhibition of cell proliferation by SARSâ€�CoV" exact="infection" post="in Vero E6 cells. FEMS Immunology and Medical Microbiology,"/>
 <result pre="R. (2020). Learning from the past: Possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019â€�nCoV."/>
 <result pre="Bellamy, R., &amp;amp; Garner, P. (2006). SARS: Systematic review of" exact="treatment" post="effects. PLoS Medicine, 3(9), 1525â€&quot;1531. e34310.1371/journal.pmed.0030343 Su, H., &amp;amp;"/>
 <result pre="without methotrexate, compared with starting methotrexate with prednisone within stepâ€�up" exact="treatment" post="strategies in early rheumatoid arthritis: An indirect comparison of"/>
 <result pre="S., â€¦ Lu, Lu (2020). Inhibition of SARSâ€�CoVâ€�2 (previously 2019â€�nCoV)" exact="infection" post="by a highly potent panâ€�coronavirus fusion inhibitor targeting its"/>
 <result pre="11, 1â€&quot;3. 10.1038/s41423-020-0374-2 collab: Xinhua Daily . (2020). China optimizes" exact="treatment" post="for COVIDâ€�19. Retrieved from http://english.www.gov.cn/news/topnews/202003/07/content_WS5e62fff1c6d0c201c2cbdb82.html Xu, X., Liu, Y.,"/>
 <result pre="X., Deng, S. Q., &amp;amp; Peng, B. (2020). In silico" exact="screening" post="of Chinese herbal medicines with the potential to directly"/>
</results>
